Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 178 entries
View as:

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT00600015 Org: User:
Start: 02/29/08 End: 02/28/09 Due: 02/28/10

Sarah Cannon Outcomes Registry

Phase: N/A Priority: Normal
NCT ID: NCT02356822 Org: User:
Start: 12/31/14 End: 12/31/24 Due: 12/31/25

CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas

Phase: N/A Priority: Normal
NCT ID: NCT00540579 Org: User:
Start: 11/30/07 End: 01/31/11 Due: 01/31/12

Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00611689 Org: User:
Start: 07/31/04 End: 04/30/11 Due: 04/30/12

PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00611793 Org: User:
Start: 10/31/04 End: 01/31/09 Due: 01/31/10

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT00456261 Org: User:
Start: 03/31/07 End: 09/30/12 Due: 09/30/13

Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00193362 Org: User:
Start: 06/30/04 End: 09/30/07 Due: 09/30/08

Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00193310 Org: User:
Start: 11/30/00 End: 01/31/09 Due: 01/31/10

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

Phase: N/A Priority: Normal
NCT ID: NCT02843074 Org: User:
Start: 09/21/16 End: 10/05/21 Due: 10/05/22

Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00629499 Org: User:
Start: 04/30/08 End: 09/30/10 Due: 09/30/11

Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00193388 Org: User:
Start: 09/30/02 End: 02/28/07 Due: 02/28/08

Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00193570 Org: User:
Start: 02/28/02 End: 01/31/09 Due: 01/31/10

Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00392392 Org: User:
Start: 10/31/06 End: 12/31/11 Due: 12/31/12

Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00193440 Org: User:
Start: 04/30/02 End: 01/31/09 Due: 01/31/10

Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT01401959 Org: User:
Start: 09/23/11 End: 04/03/17 Due: 04/03/18

Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01033032 Org: User:
Start: 12/31/09 End: 10/31/14 Due: 10/31/15

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00695292 Org: User:
Start: 06/30/08 End: 09/30/12 Due: 09/30/13

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02887248 Org: User:
Start: 01/12/17 End: 05/01/20 Due: 05/01/21

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

Phase: N/A Priority: Normal
NCT ID: NCT06773910 Org: User:
Start: 03/11/25 End: 09/30/32 Due: 09/30/33

Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01113632 Org: User:
Start: 07/31/10 End: 08/31/16 Due: 08/31/17

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02291913 Org: User:
Start: 12/18/14 End: 01/31/19 Due: 01/31/20

Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas

Phase: N/A Priority: Normal
NCT ID: NCT00837031 Org: User:
Start: 02/28/09 End: 06/30/12 Due: 06/30/13

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

Phase: N/A Priority: Normal
NCT ID: NCT01934894 Org: User:
Start: 05/31/14 End: 04/30/17 Due: 04/30/18

A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01076504 Org: User:
Start: 12/31/09 End: 03/31/15 Due: 03/31/16

Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

Phase: N/A Priority: Normal
NCT ID: NCT00193622 Org: User:
Start: 04/30/04 End: 01/31/09 Due: 01/31/10